Compare Adobe Systems Inc (ADBE) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? Adobe Systems Inc trades at $258.49 (market cap $104.82B), while Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B). The key difference: Adobe Systems Inc is far larger — about 3.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Adobe Systems Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ADBE | ALNY | |
|---|---|---|
Market Cap | $104.82B | $29.60B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $491.22 |
52-Week Low | $193.41 | $205.48 |
Enterprise Value | $106.26B | $27.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $256.30, down 6.1% on the day amid broader tech sector weakness. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $5.96 versus $5.82 expected. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $252. Revenue grew to $23.77B in 2025 with impressive 28.69% net margins.
Adobe presents a compelling value opportunity trading below analyst consensus targets despite AI competition concerns. The company's robust cash flow generation and market leadership in creative software support long-term growth, though investor sentiment remains cautious due to CEO transition and AI disruption risks. Wall Street maintains a buy-heavy rating with $248.86 average price target.
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
